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Background
The Wnt family consists of secreted extracellular glycopro-
teins that induce an intracellular signaling pathway
involved in many events during embryogenesis and adult
tissue maintenance. As they are involved in a large variety
of cellular processes, errors in the Wnt-signaling pathways
can lead for example to degenerative diseases and cancer
and in embryos to developmental defects. So far there are
19 genes encoding for Wnt-proteins found in both mouse
and human. Wnt-proteins are highly conserved, both with
each other as well as between species. They all consist of
about 350–400 amino acids, have multiple cysteines, are
hydrophobic (possibly due to a conserved palmitoyla-
tion) and have a high pI.
Recombinant Wnt proteins are needed as important tools
for example in basic research concerning developmental
biology and Wnt function as well as for medical applica-
tions (e.g. therapeutics, stem cells). However, production
of recombinant Wnt proteins in E. coli is very challenging,
because their hydrophobicity and several disulfide bonds
make their proper folding extremely difficult. In this
study, strategies for the expression of Wnt proteins in E.
coli are investigated.
Results
A process for production of active murine Wnt1 in E. coli
has recently been developed in our laboratory [1]. This
was the first time a Wnt protein has been produced in an
active form using a prokaryotic expression system. Here
Wnt1 was targeted to the periplasmic space which has
more oxidative conditions for proper folding than the
bacterial cytoplasm. Currently, processes for the expres-
sion of other Wnt proteins are developed.
Two different expression strategies are being followed.
First, since the folding in the bacterial cytosol for disulfide
bond-containing proteins is very difficult, one option is to
let the recombinant proteins aggregate as inclusion bodies
and refold them later in vitro. Advantages of using inclu-
sion bodies for expression include for example larger yield
of recombinant protein and fewer purification steps.
The second strategy utilizes cytoplasmic expression and
thioredoxin reductase deficient host strains. In these host
strains the cytoplasm is more oxidative than in wild type
E. coli facilitating disulfide bond formation and folding.
For both strategies some encouraging preliminary results
have been obtained. The expression conditions are cur-
rently optimized followed by protein purification (and
refolding) as well as activity tests.
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